ZBIO — Zenas BioPharma Share News
0.000.00%
Last trade - 00:00- $1.66bn
- $1.40bn
- $10.00m
Brief: Zenas BioPharma Files For Offering Of Up To 7.0 Million Shares Of Common Stock By The Selling Stockholder - SEC Filing
Zenas BioPharma, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zenas Biopharma Says Phase 3 Indigo Trial Of Obexelimab Meets Primary And All Key Secondary Endpoints
Brief: Zenas Biopharma Announces First Subject Dosed In Phase 1 Clinical Trial Of Zb021, A Novel, Potentially Best-In-Class Oral Il-17Aa/Af Inhibitor
Brief: Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Entergy, US natgas stocks, Brown-Forman, Datacentrex
U.S. STOCKS ON THE MOVE-Entergy, IDEX Corp, Quanta Services
Zenas BioPharma slides on $300 mln convertible bond, stock sales
Zenas BioPharma drops on convertible, equity offerings
Brief: Zenas Biopharma Announces Proposed Concurrent Public Offerings Of Convertible Senior Notes Due 2032 And Common Stock
Brief: Zenas Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Brief: Zenas Biopharma Announces Late-Breaking Platform Presentation Of Results From Phase 2 Moonstone Trial Of Obexelimab In Relapsing Multiple Sclerosis At Actrims Forum 2026
U.S. RESEARCH ROUNDUP-Brunswick, Parker-Hannifin, XPLR Infrastructure
Zenas plummets 50% after weak data for immune disorder drug
Zenas shares plunge on weaker-than-expected data for immune disorder drug (updated)
Zenas BioPharma's immune disorder drug meets main goal in late-stage trial
NASDAQ RESUMED AT 07:35 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:00 AM